New Cancer drug for Lung cancer patients.......

Buzzard
Buzzard Member Posts: 3,043 Member
A new drug to combat a certain type of lung cancer is being hailed today as an "amazing development" by medical experts.

The drug crizotinib (Xalkori), manufactured by Pfizer and approved last week by the Food and Drug Administration, is intended for a small number of patients.

The twice-daily capsules are meant for patients with non-small cell lung cancer who have a unique gene known as an abnormal anaplastic lymphoma kinase(ALK). An ALK gene causes cancer growth and development.

Pfizer held a panel today to discuss the implications of the new drug.

"What we've seen from studies to date is that this pill does have significant activity," said Dr. Alice Shaw, a thoracic oncologist at Massachusetts General Hospital Cancer Center, who took part in crizotinib studies. "For about 60 percent of patients, they will have a significant shrinkage in their tumors and what the preliminary studies have also shown is that the median or average duration of response is on the order of 10 months."

Pfizer Inc./AP Photo
In this product image provided by Pfizer... View Full Size

Pfizer Inc./AP Photo
In this product image provided by Pfizer Inc., the drug Xalkori is displayed. CT Scans Detect Lung Cancer Early Watch Video
Lung Cancer Screening Means More Patients Watch Video
Screen, But Quit Smoking Too Watch Video
Lung Cancer Drug Blocks Proteins

Crizotinib works by blocking the proteins produced by the ALK gene. The FDA also approved a diagnostic test by Abbott Laboratories that screens for the gene. Patients found to have the gene would be able to be prescribed the pill, although chemotherapy and radiation therapies would remain options.

The most common side effects, according to Medpage Today, reported in patients taking crizotinib were vision disorders, nausea and edema.

About 187,000, or 85 percent of the 220,000 lung cancer cases diagnosed yearly, are non-small cell lung cancer. Of those cases, less than 7 percent have the ALK gene.

Dr. David Carbone, a lung cancer specialist at Vanderbilt University, one of the sites that tested the drug, told The Associated Press that for those patients, crizotinib made a huge difference. "It's pretty exciting," he said.

"For many patients, this drug has been a lifesaver," Massachusetts General's Shaw told ABC News. "For many patients, they experienced a very immediate and significant relief in their symptoms, sometimes within the first week."

Dr. Roy S. Herbst, chief of medical oncology at Yale Cancer Center, said that crizotinib's FDA approval was a "pivotal milestone" in lung cancer treatment.

"It's another example of how we are using molecular medicine to effectively treat a subset of cancer patients," Herbst told ABC News via email.

Comments

  • Buckwirth
    Buckwirth Member Posts: 1,258 Member
    Interesting stuff
    Thanks Buzz!
  • Buzzard
    Buzzard Member Posts: 3,043 Member
    Buckwirth said:

    Interesting stuff
    Thanks Buzz!

    Wolfen sicked me on this........
    It seems as someone else in here said...I think 2011 will be great for a lot of people.....We can only hope....
  • Buzzard said:

    Wolfen sicked me on this........
    It seems as someone else in here said...I think 2011 will be great for a lot of people.....We can only hope....

    Great news Buzz........ hope
    Great news Buzz........ hope is what is driving us all...